55 results about "Hydroxychloroquine Sulfate" patented technology

The invention relates to an industrial preparation method of hydroxychloroquine sulfate, which comprises heating 4, 7-dichloroquinoline and hydroxychloroquine side chain at refluxing temperature to 120-125 DEG C, allowing reaction to obtain hydroxychloroquine, and reacting with sulfuric acid to obtain hydroxychloroquine sulfate. The method can obtain high-purity hydroxychloroquine sulfate with single impurity less than or equal to 0.1% and purity higher than or equal to 99.5%; and has less preparation procedures, simple process, high product yield, good quality, low environmental pollution, no use of highly toxic solvent, and is easy for industrial production.

The invention provides an industrial production method for hydroxychloroquine sulfate, which includes the following steps: enabling 4.7-dichloroquinoxaline and 5-(N-ethyl-N-ethoxyl)-2-amino pentane to react under gas shield for 13-24 h at a gradually increased temperature of 120-130 DEG C to obtain hydroxychloroquine; preparing the hydroxychloroquine sulfate after the reaction between the hydroxychloroquine and an alcohol sulfate solution at the temperature of 20-30 DEG C. According to the method, the yield of the obtained crude product of the hydroxychloroquine is not smaller than 85%, the yield of the obtained hydroxychloroquine sulfate is not smaller than 85%, the yield of the obtained hydroxychloroquine sulfate HPLC is not smaller than 99.5%, the yield of single impurity is not larger than 0.1%, so that requirements of United States Pharmacopeia is met; the novel method is simple in procedure, is environment-friendly and easy in industrial production.

The invention discloses a technology for treating a hydroxychloroquine sulfate raw medicament. The treatment technology comprises the following steps of: performing wet granulation on the hydroxychloroquine sulfate raw medicament by using absolute ethanol as a wetting agent, and drying. The moisture absorption of the hydroxychloroquine sulfate treated by the treatment technology is obviously reduced. The invention also discloses a method for preparing the hydroxychloroquine sulfate tablets by using the hydroxychloroquine sulfate obtained by the treatment technology. The method is easy to operate, can be used for well solving the adaptability with equipment in granulation and tabletting processes, improving the reproducibility of the process and stability of the quality, and has a good commercial prospect.

The invention relates to a preparation method of a medical intermediate 4,7-dichloroquinoline. The 4,7-dichloroquinoline is an important intermediate of a medicine hydroxychloroquine sulfate for treating discoid lupus erythematosus and systemic lupus erythematosus. The preparation method comprises the following steps: performing hydrolysis and acid adjustment on 4-hydroxyl-7-chlorine-quinoline-3-carboxylic acid ethyl ester by using 10% sodium hydroxide solution to prepare 4-hydroxyl-7-chlorine-quinoline-3-carboxylic acid; performing decarboxylation to produce 4-hydroxyl-7-chloroquinoline; and chlorinating the 4-hydroxyl-7-chloroquinoline by using phosphorus oxychloride to obtain 4,7-dichloroquinoline crude products; and performing one-step refining to obtain the products. The purity of the prepared products is more than or equal to 99% and the total yield of the products is more than or equal to 70%; raw materials are easily available; the process is simple; the yield and the purity are high in each step; and the preparation method is suitable for industrialized production.

The invention discloses a preparation method of high-purity hydroxychloroquine sulfate. The method uses 4,7-dichloroquinoline and hydroxychloroquine side chain as raw materials to directly prepare hydroxychloroquine hydrochloride, hydroxychloroquine hydrochloride is neutralized with sodium alcoholate or potassium alcoholate, filtered, concentrated, beaten and crystallized to obtain hydroxychloroquine refined product, and the hydroxychloroquine refined product finally is subjected to salifying reaction with sulfuric acid in a certain proportion of pure aqueous solution to obtain hydroxychloroquine sulfate. The method avoids the use of phenol or its catalyst in the process of preparing hydroxychloroquine, avoids the extraction operation in the post-treatment, has high product purity, and basically does not generate waste water in the production process. The method is convenient to operate and has high yield, the HPLC purity of prepared hydroxychloroquine sulfate is more than or equal to99.6%, and maximum single impurity is less than or equal to 0.1%, and that method is more suitable for industrial production.

The invention discloses a hydroxychloroquine sulfate crystal form A and a preparation method thereof and uses means of XRPD, DSC and IR for representation. The hydroxychloroquine sulfate crystal formA provided by the invention improves the chemical stability of hydroxychloroquine sulfate, is simple in preparation method and easy in industrialized production and can provide a study foundation to development of more hydroxychloroquine sulfate dosage forms at the same time. In the preparation method provided by the invention, a sulfuric acid aqueous solution with the mass percentage being 40-60percent is used, the safety and the operability are improved, and the heat release risk generated by using concentrated sulfuric acid is effectively lowered.

The invention relates to application of artesunate as a drug for treating systemic lupus erythematosus, adopting the artesunate with a molecular formula of C19H2808 for treating the systemic lupus erythematosus. The invention overcomes the defects that the prior common drug for treating SLE, such as cyclophosphamide, glucocorticoid, mycophenolate mofetil, hydroxychloroquine sulfate, leflunomide, azathioprine and the like has multiple side effects, is expensive, influences the life quality of a patient and even causes the patient to die because of some side effects, and the like. The invention has the advantages of cheap raw materials, easy availability, non or low toxicity, no pollution, mature production technology of a artesunate finished product, stable and reliable quality and little toxic side effects. Through comparison and study on a lupus mouse show that the efficacy of the artesunate is superior to a contrast group with little side effect. Therefore, the artesunate has a favorable prospect to treat the systemic lupus erythematosus.

The invention belongs to the field of drug analysis and discloses a method for analysis of a hydroxychloroquine sulfate raw material and preparation by high performance liquid chromatography. The method can realize effective separation of related substances in hydroxychloroquine sulfate so that hydroxychloroquine sulfate quality is controlled, hydroxychloroquine sulfate raw material and preparation content is accurately determined, and hydroxychloroquine sulfate stability is indicated. The method has the advantages of strong specificity, high accuracy and simple operation.

The present invention provides a combined drug, which contains a first active ingredient artemisinin, a second active ingredient hydroxychloroquine sulfate, and an optionally pharmaceutically-acceptable excipient. According to the present invention, the combined drug can be effectively used for autoimmune disease treatment, and can reduce the hydroxychloroquine sulfate consumption under the premise of assurance of the unchanged efficacy even improvement of the efficacy so as to reduce the toxic-side effect of the hydroxychloroquine sulfate.

Two crystals of (S)-(+)-hydroxychloroquine sulfate. One crystal features diffraction peaks at 12.3 +/- 0.1 degrees, 13.1 +/- 0.1 degrees, 17.9 +/- 0.1 degrees, 22.8 + 0.1 degrees, 23.4 + 0.1 degrees, 25.1 +/- 0.1 degrees, and 26.3 +/- 0.1 degrees as 2theta angles in a powder X-ray diffraction pattern. The other crystal features diffraction peaks at 12.8 +/- 0.1 degrees, 14.5 +/- 0.1 degrees, 16.7 + 0.1 degrees, 17.6 + 0.1 degrees, 20.2 +/- 0.1 degrees, 21.4 +/- 0.1 degrees, 23.8 +/- 0.1 degrees, 25.7 +/- 0.1 degrees, and 26.0 +/- 0.1 degrees as 2theta angles in a powder X-ray diffraction pattern. Also disclosed are methods of preparing crystals of (S)-(+)-hydroxychloroquine sulfate.

The invention discloses a method for analyzing a composition of a hydroxychloroquine sulfate preparation by high performance liquid chromatography. The method comprises the following steps: a. selecting 50mg of hydroxychloroquine sulfate reference substance, and precisely weighing; b, precisely weighing 1.0 ml, 2.0 ml, 3.0 ml, 4.0 ml, 5.0 ml, 6.0 ml and 7.0 ml of the mixed solutions obtained in the step a, and putting the mixed solutions into a 10ml volumetric flask for later use; c, performing chromatographic analysis by using a chromatographic column to obtain a regression equation of a concentration C and a peak area A; and d, removing a proper amount of a mixture obtained in the step a, precisely weighing, adding a diluent to dissolve, and quantitatively diluting to prepare a solutioncontaining 0.5 mg per 1ml to obtain a test solution; and precisely measuring the test solution, adding a mobile phase, diluting to prepare a solution containing 0.05 g per 1ml as a control solution, precisely measuring 0.2 ml of the control solution, injecting the control solution into a liquid chromatograph, and adjusting sensitivity of an instrument for testing. The method for analyzing the composition of the hydroxychloroquine sulfate preparation by the high performance liquid chromatography is simple and convenient to operate, sensitive, high in accuracy, suitable for clinical hydroxychloroquine serum drug concentration monitoring and high in specificity.

The invention discloses a new use of chloroquine in prevention and control of root-knot nematodes, and belongs to the technical field of the prevention and control of root-knot nematodes. The invention relates to a use of chloroquine in prevention and control of root-knot nematodes and a use of chloroquine in inhibition of infection, development and/or oviposition of root-knot nematodes, wherein the chloroquine is chloroquine phosphate, hydroxychloroquine sulfate or quinine sulfate. The invention also relates to a use of chloroquine in preparation of a root-knot nematode pesticide or a root-knot nematode infection, development and/or oviposition inhibitor, wherein the active component of the root-knot nematode pesticide or the root-knot nematode infection, development and/or oviposition inhibitor is chloroquine phosphate, hydroxychloroquine sulfate or quinine sulfate; and the root-knot nematode pesticide or the root-knot nematode infection, development and/or oviposition inhibitor is an aqueous solution of chloroquine phosphate, hydroxychloroquine sulfate or quinine sulfate. According to the present invention, the prevention and control of root-knot nematodes with the aqueous solution of chloroquine are safe, non-toxic and effective.

The invention discloses a hydroxychloroquine sulfate and polyglutamic acid polymer, as well as a preparation method and application thereof. The hydroxychloroquine sulfate and polyglutamic acid polymer is a polymer formed by carrying out esterification reaction between hydroxychloroquine sulfate and polyglutamic acid according to a weight ratio of 1:(1-6). The hydroxychloroquine sulfate and polyglutamic acid polymer is applied to treatment of discoid lupus erythematosus and systemic lupus erythematosus. The hydroxychloroquine sulfate and the polyglutamic acid are cross-linked to obtain the hydroxychloroquine sulfate and polyglutamic acid polymer, and hydroxyls of the hydroxychloroquine sulfate are modified to change certain original physiochemical properties thereof, improve pharmaceutical activity, enhance curative effects, reduce side effects, improve the sustained release effects of the drug and reduce the medication frequency of a patient; when the hydroxychloroquine sulfate and polyglutamic acid polymer is used for treating discoid lupus erythematosus and systemic lupus erythematosus, the drug can reach a destination lesion location under protection of the polyglutamic acid in a slow degradation process, so that the aim of accurate treatment is fulfilled, and the hydroxychloroquine sulfate and polyglutamic acid polymer has a certain clinical application value.

The invention discloses a method for detecting hydroxychloroquine sulfate related substances. The method comprises the following step: carrying out separation and detection by adopting reverse liquidchromatography, wherein chromatographic conditions are as follows: a mobile phase is a mixed solvent consisting of a water-soluble organic solvent and a buffer solution; wherein the buffer solution isan ammonium acetate solution or an ammonium formate solution; wherein the pH value of the buffer solution is 9.0 to 10.5. The detection method disclosed by the invention can be used for simultaneously detecting seven impurities recorded in quality standards of hydroxychloroquine sulfate raw materials in European Pharmacopoeia 9.8 versions in hydroxychloroquine sulfate raw materials and preparations, and has the advantages of good separation effect, high sensitivity, no blank interference, low detection cost, high analysis speed and the like.

The invention discloses hydroxychloroquine sulfate and a preparation method thereof, and relates to the technical field of medicinal chemistry. The preparation method comprises the steps of mixing 4, 7-dichloroquinoline with a hydroxychloroquine side chain, carrying out heating condensation in the presence of an organic base catalyst, adding water and liquid, and carrying out cooling crystallization to obtain hydroxychloroquine; and dissolving hydroxychloroquine in an ethyl acetate and ethanol aqueous solution, heating, dissolving and clarifying, dropwise adding concentrated sulfuric acid, cooling, crystallizing, filtering and drying to obtain hydroxychloroquine sulfate. The method has the beneficial effects that a solvent-free reaction is used, and a catalyst is added, so that high pollution is avoided, the reaction process is accelerated, and the operation is simple; and meanwhile, the HPLC purity of the obtained hydroxychloroquine refined product is not less than 96.50%, the maximum single impurity content is less than 0.10%, the yield can reach 85%, the HPLC purity of hydroxychloroquine sulfate is not less than 98.00%, the maximum single impurity content is less than 0.10%, and the yield can reach 90%.

The invention relates to hydroxychloroquine sulfate as well as a crystal form and a preparation method of an enantiomer of hydroxychloroquine sulfate. The invention provides a crystal form A hydroxychloroquine sulfate. An X-ray powder diffraction pattern of the crystal form A hydroxychloroquine sulfate has characteristic peaks at 10.8 degrees, 13.0 degrees, 13.3 degrees, 16.9 degrees, 17.2 degrees, 17.5 degrees, 19.9 degrees, 21.3 degrees, 23.5 degrees, 24.0 degrees and 26.7 degrees +/-0.2 degrees, and does not contain hydroxychloroquine nitrogen oxide; the invention provides a hydroxychloroquine crystal, the X-ray powder diffraction pattern has characteristic peaks at 7.5 degrees, 14.9 degrees, 16.5 degrees, 19.2 degrees, 19.6 degrees, 22.8 degrees, 23.6 degrees and 26.7 degrees+/-0.2 degree; the invention provides an S-hydroxychloroquine sulfate monohydrate, the X-ray powder diffraction pattern has characteristic peaks at 12.2 degrees, 13.0 degrees, 14.9 degrees, 17.8 degrees, 22.7 degrees, 23.3 degrees, 25.0 degrees and 26.2 degrees +/-0.2 degrees; the invention also provides R-hydroxychloroquine sulfate, the X-ray powder diffraction pattern has characteristic peaks at 12.2 degrees, 13.0 degrees, 14.9 degrees, 17.8 degrees, 22.7 degrees, 23.3 degrees, 25.0 degrees and 26.2 degrees +/-0.2 degrees.

The invention provides a combined medicine. The combined medicine consists of artemisinin which serves as a first active ingredient, hydroxychloroquine sulfate which serves as a second active ingredient and optional pharmaceutically acceptable adjuvants. The combined medicine can be used for treating malaria more effectively, and the combined medicine can relieve drug toxicity and delay the generation of drug resistance.

The invention discloses a hydroxychloroquine sulfate sustained-release microsphere for articular cavity injection and a preparation method thereof. The preparation method comprises the following steps: dissolving a surfactant in an organic solvent to form an oil phase; adding hydroxychloroquine sulfate and gelatin into water to obtain a water phase; dropwise adding the water phase into the oil phase, stirring and emulsifying to form a W/O type emulsion; transferring the W/O emulsion into an ice bath, and adding a curing agent for cross-linking curing; and then adding isopropanol for dehydration, suction filtration, washing and drying to obtain the hydroxychloroquine sulfate sustained-release microspheres for articular cavity injection. The prepared hydroxychloroquine microspheres can stably and continuously release drugs for more than 48 hours, a sustained-release preparation is obtained, the administration frequency can be reduced, the total dosage can be reduced, the compliance of patients can be improved, and the clinical application potential is good.